| Targets |
Boc-NH-PEG2-NH-Boc is a chemical linker and does not have a specific biological target. Its function is based on chemical reactivity rather than pharmacological receptor engagement. The compound contains two Boc-protected amine groups that can be deprotected under acidic conditions to reveal free amines for further conjugation. It is used as a versatile building block in peptide synthesis, linker design, and bioconjugation strategies.
|
|---|---|
| ln Vitro |
One ligand is for an E3 ubiquitin ligase, and the other is for the target protein; these two ligands are joined by a linker to form PROTACs. The intracellular ubiquitin-proteasome system is utilized by PROTACs to specifically destroy target proteins[1].
As a chemical linker, Boc-NH-PEG2-NH-Boc does not possess intrinsic in vitro biological activity. Its value derives from its utility as a building block for synthesizing PROTACs and other bioconjugates. The Boc protecting groups are acid-labile and can be removed to expose amine groups for subsequent coupling reactions. The hydrophilic PEG2 spacer increases water solubility and provides a defined length for connecting functional moieties. |
| ln Vivo |
Boc-NH-PEG2-NH-Boc is not a pharmacologically active compound and does not exhibit in vivo biological activity. Its role is limited to chemical conjugation applications in research settings. The compound is used to synthesize PROTACs and other molecules that may subsequently demonstrate in vivo efficacy. No direct in vivo effects have been reported for this PEG linker itself.
|
| Enzyme Assay |
Not applicable. Boc-NH-PEG2-NH-Boc is a chemical linker and is not evaluated in enzyme or receptor binding assays. Standard characterization includes NMR, HPLC, and mass spectrometry to confirm structure and purity. The compound is used as a building block in organic synthesis and bioconjugation.
|
| Cell Assay |
Not applicable. Boc-NH-PEG2-NH-Boc lacks direct biological activity and is not tested in cell-based pharmacological assays. Cell culture experiments involving this compound typically use it as a synthetic intermediate to produce bioactive conjugates after deprotection and further functionalization. The linker itself is not the active testing agent in cellular models.
|
| Animal Protocol |
Not applicable. Boc-NH-PEG2-NH-Boc is not administered to animals as a therapeutic agent. In vivo studies may utilize this compound as a component of larger conjugates synthesized prior to animal experimentation. The linker itself is not the subject of pharmacokinetic or pharmacodynamic evaluation.
|
| ADME/Pharmacokinetics |
Not applicable. Boc-NH-PEG2-NH-Boc is a research chemical not developed as a pharmaceutical agent. Pharmacokinetic properties have not been characterized. It is handled as a laboratory reagent with standard storage conditions.
|
| Toxicity/Toxicokinetics |
Not applicable. Boc-NH-PEG2-NH-Boc is not a therapeutic drug, and systematic toxicity data are not available. Standard laboratory safety practices should be followed when handling this compound. It is intended for research use only.
|
| References | |
| Additional Infomation |
Boc-NH-PEG2-NH-Boc is a PEG-based PROTAC linker used in the synthesis of protein degraders. The compound contains two Boc-protecting groups and a hydrophilic PEG spacer. The Boc protecting groups are acid-labile. The hydrophilic PEG linker increases water solubility. The compound is used as a versatile building block in peptide synthesis, linker design, and bioconjugation strategies.
|
| Molecular Formula |
C16H32N2O6
|
|---|---|
| Molecular Weight |
348.435
|
| Exact Mass |
348.226
|
| CAS # |
475591-59-4
|
| PubChem CID |
11473508
|
| Appearance |
Colorless to light yellow liquid
|
| LogP |
2.85
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
13
|
| Heavy Atom Count |
24
|
| Complexity |
338
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C(OC(C)(C)C)(=O)NCCOCCOCCNC(OC(C)(C)C)=O
|
| InChi Key |
IBOKAWABMPUDFK-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C16H32N2O6/c1-15(2,3)23-13(19)17-7-9-21-11-12-22-10-8-18-14(20)24-16(4,5)6/h7-12H2,1-6H3,(H,17,19)(H,18,20)
|
| Chemical Name |
tert-butyl N-[2-[2-[2-[(2-methylpropan-2-yl)oxycarbonylamino]ethoxy]ethoxy]ethyl]carbamate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8699 mL | 14.3497 mL | 28.6993 mL | |
| 5 mM | 0.5740 mL | 2.8699 mL | 5.7399 mL | |
| 10 mM | 0.2870 mL | 1.4350 mL | 2.8699 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
